CEO Todd Zavodnick (Dermavant)

With long-term da­ta in hand, Vivek Ra­maswamy's Der­ma­vant team dash­es to the goal line with top­i­cal pso­ri­a­sis con­tender

Months af­ter tout­ing pos­i­tive da­ta from two piv­otal Phase II­Is, Vivek Ra­maswamy’s Der­ma­vant team is back with long-term da­ta to back its pso­ri­a­sis can­di­date tap­inarof — and it’s head­ed for the FDA.

About 91% of the 1,025 pa­tients in Der­ma­vant’s PSOAR­ING 1 and 2 Phase III stud­ies opt­ed to roll in­to PSOAR­ING 3, a long-term safe­ty analy­sis, CEO Todd Za­vod­nick said. But the study end­ed up be­ing much more than a safe­ty tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.